| AVS 65th International Symposium & Exhibition | |
| Nanometer-scale Science and Technology Division | Monday Sessions |
| Session NS+2D+AN+EM+MN+MP+PC+RM-MoM |
| Session: | IoT Session: Nanostructured Devices and Sensors |
| Presenter: | Dean Ho, UCLA |
| Correspondent: | Click to Email |
Dean Ho, Ph.D.
Nanodiamonds have emerged as promising candidates for clinical drug delivery due to their ability to carry a wide range of candidate therapies, unique surface properties, and biological tolerability. This lecture will highlight our recent clinical trial to validate a nanodiamond-embedded biomaterial for root canal therapy indications [1]. We will discuss the broad spectrum of efficacy, safety, characterization, and other studies that bridged in vitro with preclinical and downstream in-human studies. This lecture will also discuss upcoming clinical nanodiamond-based drug carrier studies, as well as our work in augmented artificial intelligence (AI) to develop globally optimized nanodiamond-modified therapy. Pairing nanodiamond platforms with augmented AI will lead to major advances in drug development and markedly improve response rates and treatment outcomes for a broad spectrum of disorders. Our recent clinical trials using these powerful combination therapy optimization technologies and digital health platforms to scale their implementation to usher in a new era of nanomedicine-based treatment will also be discussed [2].
1. Lee et al., Proceedings of the National Academy of Sciences, 2017
2. Zarrinpar et al., Science Translational Medicine, 2016